These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29477400)

  • 1. A Comparison of Different Approaches for Costing Medication Use in an Economic Evaluation.
    Heslin M; Babalola O; Ibrahim F; Stringer D; Scott D; Patel A
    Value Health; 2018 Feb; 21(2):185-192. PubMed ID: 29477400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.
    Brennan A; Bansback N; Nixon R; Madan J; Harrison M; Watson K; Symmons D
    Rheumatology (Oxford); 2007 Aug; 46(8):1345-54. PubMed ID: 17562686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness of TNF-Blocker Injection Spacing for Patients with Established Rheumatoid Arthritis in Remission: An Economic Evaluation from the Spacing of TNF-Blocker Injections in Rheumatoid Arthritis Trial.
    Vanier A; Mariette X; Tubach F; Fautrel B;
    Value Health; 2017 Apr; 20(4):577-585. PubMed ID: 28407999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom.
    Botteman MF; Hay JW; Luo MP; Curry AS; Wong RL; van Hout BA
    Rheumatology (Oxford); 2007 Aug; 46(8):1320-8. PubMed ID: 17545684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.
    Kievit W; Adang EM; Fransen J; Kuper HH; van de Laar MA; Jansen TL; De Gendt CM; De Rooij DJ; Brus HL; Van Oijen PC; Van Riel PC
    Ann Rheum Dis; 2008 Sep; 67(9):1229-34. PubMed ID: 18174220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'.
    Hülsemann JL; Ruof J; Zeidler H; Mittendorf T
    Rheumatol Int; 2006 Jun; 26(8):704-11. PubMed ID: 16261384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years.
    Sany J; Cohen JD; Combescure C; Bozonnat MC; Roch-Bras F; Lafon G; Daurès JP
    Rheumatology (Oxford); 2009 Oct; 48(10):1236-41. PubMed ID: 19620209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost of illness in rheumatoid arthritis in Germany in 1997-98 and 2002: cost drivers and cost savings.
    Kirchhoff T; Ruof J; Mittendorf T; Rihl M; Bernateck M; Mau W; Zeidler H; Schmidt RE; Merkesdal S
    Rheumatology (Oxford); 2011 Apr; 50(4):756-61. PubMed ID: 21149243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologicals for rheumatoid arthritis.
    Tugwell P; Singh JA; Wells GA
    BMJ; 2011 Jul; 343():d4027. PubMed ID: 21798970
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
    Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis.
    Bansback NJ; Ara R; Barkham N; Brennan A; Fraser AD; Conway P; Reynolds A; Emery P
    Rheumatology (Oxford); 2006 Aug; 45(8):1029-38. PubMed ID: 16782734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate.
    Vera-Llonch M; Massarotti E; Wolfe F; Shadick N; Westhovens R; Sofrygin O; Maclean R; Yuan Y; Oster G
    Rheumatology (Oxford); 2008 Apr; 47(4):535-41. PubMed ID: 18356179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
    Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Financial cost of early rheumatoid arthritis in the first year of medical attention: three clinical scenarios in a third-tier university hospital in Colombia].
    Mora C; González A; Díaz J; Quintana G
    Biomedica; 2009 Mar; 29(1):43-50. PubMed ID: 19753838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.
    Kobelt G; Lindgren P; Singh A; Klareskog L
    Ann Rheum Dis; 2005 Aug; 64(8):1174-9. PubMed ID: 15708879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics of emerging therapies for rheumatoid arthritis. Based on a presentation by Arthur Kavanaugh, MD.
    Am J Manag Care; 1999 Jun; 5(8 Suppl):S483-7; discussion S487-8. PubMed ID: 10538856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Costs of rheumatoid arthritis in Hungary.
    Péntek M; Kobelt G; Czirják L; Szekanecz Z; Poór G; Rojkovich B; Polgár A; Genti G; Kiss CG; Brodszky V; Májer I; Gulácsi L
    J Rheumatol; 2007 Jun; 34(6):1437. PubMed ID: 17552071
    [No Abstract]   [Full Text] [Related]  

  • 20. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.